Meeting Banner
Abstract #2801

DCE-MRI at 3T in Patients with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy

Tristan Barrett1, Andrew Gill1,2, Masako Kataoka1, Vincent J. Gnanapragasam3, Andrew Priest1,2, Ilse Joubert1, Mary McLean2,4, Martin J. Graves1, David J. Lomas1, John R. Griffiths2, David Neal3,5, Evis Sala1

1Radiology, Addenbrooke's Hospital, Cambridge, United Kingdom; 2Medical Physics, Addenbrooke's Hospital, Cambridge, United Kingdom; 3Urology, Addenbrooke's Hospital, Cambridge, United Kingdom; 4 Cambridge Research Institute, Cancer Research UK,, Cambridge, United Kingdom; 5Cambridge Research Institute, Cancer Research UK, Cambridge, United Kingdom

Prostate cancer is the commonest malignancy in UK men. Androgen deprivation therapy (ADT) remains an important treatment. However, 51% eventually develop resistance, making it necessary to identify quantitative markers that demonstrate ADT response. We used dynamic-contrast-enhancement (DCE)-MRI to measure permeability parameters before and 3 months after ADT in 12 patients with biopsy-proven prostate cancer. There was a significant reduction in all parameters measured (Ktrans, kep, Ve, IAUGC-90), whereas normal tissue showed no significant change. These results suggest that DCE-MRI has potential to monitor ADT response and select to patients with AD resistance at early time-points, allowing consideration of other treatments.